Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories



Joanne Blum, M.D., Ph.D., FACP

Joanne Blum, M.D., Ph.D., FACP

Provider Type: Physician

  • Hematology
  • Medical Oncology
Board Certifications:
  • Medical Oncology
  • Internal Medicine

General Summary

Joanne L. Blum, M.D., Ph.D., FACP, has clinical and research interests in the field of breast cancer and genetic counseling for breast and ovarian cancers. Dr. Blum is a member of the Breast Cancer Committee for The US Oncology Network.


Dr. Blum received an M.D. from the University of Maryland School of Medicine, in 1979. She completed her internal medicine training at Michael Reese Hospital in Chicago and the University of Michigan, Ann Arbor, Michigan, in 1982. She did a clinical fellowship, 1982-1985, and research fellowship, 1985-1987, in hematology and oncology at the University of Michigan, Ann Arbor. She received a Ph.D. in cellular and molecular biology from the University of Michigan, in 1987.


  • Recall injury from vinblastine: a case report.

    Journal of Clinical Oncology, 2007

  • Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 Mutation Carriers.

    Clinical Breast Cancer, 2007

  • Phase 2 study of weekly nab-Paclitaxel for the treatment of patients with metastatic breast cancer heavily pretreated with taxanes.

    Clinical Breast Cancer, 2007

  • Capecitabine/taxane combination therapy: evolving clinical utility in breast cancer.

    Clinical Breast Cancer, 2006

  • Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.

    Journal of Clinical Oncology, 2006

Show all Publications
  • Results of a Phase III trial doxoroubicin/cyclophosphamide (AC) compared to docetaxel/cyclophosphamide (TC) as adjuvant therapy for operable breast cancer.

    Journal of Clinical Oncology, 2006

  • Are granulocyte colony-stimulating growth factors (CSF’s) needed to prevent febrile neutropenia (FN) for course #1 of adjuvant chemotherapy with “standard” doxorubicin-cyclophosphamide (ASC) Results from two consecutive US Oncology community adjuvant trials.

    Breast Cancer Research and Treatment, 2006

  • Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. 

    Journal of Clinical Oncology, 2006

Accolades & Memberships

Phi Beta Kappa, University of Pennsylvania, 1975; Alpha Omega Alpha Honor Medical Society, 1979; American Medical Women’s Citation for Scholastic Achievement, 1979; faculty member in Internal Medicine, hematology and oncology, University of Texas Southwestern Medical School at Dallas, 1987-1992, and clinical faculty Member since 1992; Distinguished Young Researcher Award, University of Texas Southwestern Medical School at Dallas, 1990; American Cancer Society Clinical Oncology Cancer Development Award, 1989-1992; Fellow of the American College of Physicians, 2002; member, American Society of Clinical Oncology, American Association of Cancer Research, American Association of Human Genetics, The American College of Physicians, The Texas Society of Medical Oncology, Texas Medical Association. In 2009 D Magazine elected Dr. Blum as one of the best hematology oncologists in Dallas, Texas.